Michael C Ferraro1,2, Matthew K Bagg3,4,5, Michael A Wewege1,2, Aidan G Cashin1,6, Hayley B Leake1,7, Rodrigo R N Rizzo1,2, Matthew D Jones1,2, Sylvia M Gustin1,8, Richard Day9,10, Colleen K Loo11,12, James H McAuley1,2. 1. Centre for Pain IMPACT, Neuroscience Research Australia, Sydney, NSW, Australia. 2. School of Health Sciences, University of New South Wales, Sydney, Australia. 3. Centre for Pain IMPACT, Neuroscience Research Australia, Sydney, NSW, Australia. m.bagg@neura.edu.au. 4. Prince of Wales Clinical School, University of New South Wales, Sydney, Australia. m.bagg@neura.edu.au. 5. New College Village, University of New South Wales, Sydney, Australia. m.bagg@neura.edu.au. 6. Prince of Wales Clinical School, University of New South Wales, Sydney, Australia. 7. IIMPACT in Health, University of South Australia, Adelaide, Australia. 8. School of Psychology, University of New South Wales, Sydney, Australia. 9. Clinical Pharmacology & Toxicology, St. Vincent's Hospital, Sydney, Australia. 10. St. Vincent's Clinical School, Faculty of Medicine, University of New South Wales, Sydney, Australia. 11. School of Psychiatry, University of New South Wales, Sydney, Australia. 12. Black Dog Institute, Sydney, Australia.
Abstract
BACKGROUND: Antidepressant medicines are used to manage symptoms of low back pain. The efficacy, acceptability, and safety of antidepressant medicines for low back pain (LBP) are not clear. We aimed to evaluate the efficacy, acceptability, and safety of antidepressant medicines for LBP. METHODS: We searched CENTRAL, MEDLINE, Embase, CINAHL, ClinicalTrials.gov , the EU Clinical Trials Register, and the WHO International Clinical Trial Registry Platform from inception to May 2020. We included published and trial registry reports of RCTs that allocated adult participants with LBP to receive an antidepressant medicine or a placebo medicine. Pairs of authors independently extracted data in duplicate. We extracted participant characteristics, study sample size, outcome values, and measures of variance for each outcome. We data using random-effects meta-analysis models and calculated estimates of effects and heterogeneity for each outcome. We formed judgments of confidence in the evidence in accordance with GRADE. We report our findings in accordance with the PRISMA statement. We prespecified all outcomes in a prospectively registered protocol. The primary outcomes were pain intensity and acceptability. We measured pain intensity at end-of-treatment on a 0-100 point scale and considered 10 points the minimal clinically important difference. We defined acceptability as the odds of stopping treatment for any reason. RESULTS: We included 23 RCTs in this review. Data were available for pain in 17 trials and acceptability in 14 trials. Treatment with antidepressants decreased pain intensity by 4.33 points (95% CI - 6.15 to - 2.50) on a 0-100 scale, compared to placebo. Treatment with antidepressants increased the odds of stopping treatment for any reason (OR 1.27 [95% CI 1.03 to 1.56]), compared to placebo. CONCLUSIONS: Treatment of LBP with antidepressants is associated with small reductions in pain intensity and increased odds of stopping treatment for any reason, compared to placebo. The effect on pain is not clinically important. The effect on acceptability warrants consideration. These findings provide Level I evidence to guide clinicians in their use of antidepressants to treat LBP. TRIAL REGISTRATION: We prospectively registered the protocol for this systematic review on PROSPERO ( CRD42020149275 ).
BACKGROUND: Antidepressant medicines are used to manage symptoms of low back pain. The efficacy, acceptability, and safety of antidepressant medicines for low back pain (LBP) are not clear. We aimed to evaluate the efficacy, acceptability, and safety of antidepressant medicines for LBP. METHODS: We searched CENTRAL, MEDLINE, Embase, CINAHL, ClinicalTrials.gov , the EU Clinical Trials Register, and the WHO International Clinical Trial Registry Platform from inception to May 2020. We included published and trial registry reports of RCTs that allocated adult participants with LBP to receive an antidepressant medicine or a placebo medicine. Pairs of authors independently extracted data in duplicate. We extracted participant characteristics, study sample size, outcome values, and measures of variance for each outcome. We data using random-effects meta-analysis models and calculated estimates of effects and heterogeneity for each outcome. We formed judgments of confidence in the evidence in accordance with GRADE. We report our findings in accordance with the PRISMA statement. We prespecified all outcomes in a prospectively registered protocol. The primary outcomes were pain intensity and acceptability. We measured pain intensity at end-of-treatment on a 0-100 point scale and considered 10 points the minimal clinically important difference. We defined acceptability as the odds of stopping treatment for any reason. RESULTS: We included 23 RCTs in this review. Data were available for pain in 17 trials and acceptability in 14 trials. Treatment with antidepressants decreased pain intensity by 4.33 points (95% CI - 6.15 to - 2.50) on a 0-100 scale, compared to placebo. Treatment with antidepressants increased the odds of stopping treatment for any reason (OR 1.27 [95% CI 1.03 to 1.56]), compared to placebo. CONCLUSIONS: Treatment of LBP with antidepressants is associated with small reductions in pain intensity and increased odds of stopping treatment for any reason, compared to placebo. The effect on pain is not clinically important. The effect on acceptability warrants consideration. These findings provide Level I evidence to guide clinicians in their use of antidepressants to treat LBP. TRIAL REGISTRATION: We prospectively registered the protocol for this systematic review on PROSPERO ( CRD42020149275 ).
Entities:
Keywords:
Analgesics; Antidepressants; Drug therapy; Low back pain; Meta-analysis; Review
Authors: Crystian B Oliveira; Chris G Maher; Rafael Z Pinto; Adrian C Traeger; Chung-Wei Christine Lin; Jean-François Chenot; Maurits van Tulder; Bart W Koes Journal: Eur Spine J Date: 2018-07-03 Impact factor: 3.134
Authors: Christopher M Williams; Christopher G Maher; Mark J Hancock; James H McAuley; Andrew J McLachlan; Helena Britt; Salma Fahridin; Christopher Harrison; Jane Latimer Journal: Arch Intern Med Date: 2010-02-08
Authors: Jasmina I Ivanova; Howard G Birnbaum; Matt Schiller; Evan Kantor; Bryan M Johnstone; Ralph W Swindle Journal: Spine J Date: 2011-05-20 Impact factor: 4.166
Authors: Robert H Dworkin; Dennis C Turk; Kathleen W Wyrwich; Dorcas Beaton; Charles S Cleeland; John T Farrar; Jennifer A Haythornthwaite; Mark P Jensen; Robert D Kerns; Deborah N Ader; Nancy Brandenburg; Laurie B Burke; David Cella; Julie Chandler; Penny Cowan; Rozalina Dimitrova; Raymond Dionne; Sharon Hertz; Alejandro R Jadad; Nathaniel P Katz; Henrik Kehlet; Lynn D Kramer; Donald C Manning; Cynthia McCormick; Michael P McDermott; Henry J McQuay; Sanjay Patel; Linda Porter; Steve Quessy; Bob A Rappaport; Christine Rauschkolb; Dennis A Revicki; Margaret Rothman; Kenneth E Schmader; Brett R Stacey; Joseph W Stauffer; Thorsten von Stein; Richard E White; James Witter; Stojan Zavisic Journal: J Pain Date: 2007-12-11 Impact factor: 5.820
Authors: Jürg Schliessbach; Andreas Siegenthaler; Lukas Bütikofer; Andreas Limacher; Peter Juni; Pascal H Vuilleumier; Ulrike Stamer; Lars Arendt-Nielsen; Michele Curatolo Journal: PLoS One Date: 2018-05-09 Impact factor: 3.240
Authors: Nathan Risch; Jonathan Dubois; Katia M'bailara; Irena Cussac; Bruno Etain; Raoul Belzeaux; Caroline Dubertret; Emmanuel Haffen; Raymund Schwan; Ludovic Samalin; Paul Roux; Mircea Polosan; Marion Leboyer; Philippe Courtet; Emilie Olié Journal: J Clin Med Date: 2022-02-08 Impact factor: 4.241
Authors: Dena Zeraatkar; Matthew Adam Cooper; Arnav Agarwal; Robin W M Vernooij; Gareth Leung; Kevin Loniewski; Jared E Dookie; Muhammad Muneeb Ahmed; Brian Y Hong; Chris Hong; Patrick Hong; Rachel Couban; Thomas Agoritsas; Jason W Busse Journal: BMJ Open Date: 2022-08-04 Impact factor: 3.006